These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Insights into anti-tumor immunity Jani S; Church CD; Nghiem P Front Immunol; 2023; 14():1172913. PubMed ID: 37287968 [TBL] [Abstract][Full Text] [Related]
13. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Moujaess E; Haddad FG; Eid R; Kourie HR Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445 [TBL] [Abstract][Full Text] [Related]
14. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Sweis RF; Galsky MD Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Komatsubara KM; Carvajal RD Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938 [TBL] [Abstract][Full Text] [Related]
16. The next generation of immunotherapy: keeping lung cancer in check. Somasundaram A; Burns TF J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399 [TBL] [Abstract][Full Text] [Related]
17. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Swe T; Kim KB Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239 [TBL] [Abstract][Full Text] [Related]
18. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases. Ren Y; Lv Q; Yue W; Liu B; Zou Z Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042 [TBL] [Abstract][Full Text] [Related]
19. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901 [TBL] [Abstract][Full Text] [Related]
20. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. Choi FD; Kraus CN; Elsensohn AN; Carley SK; Lehmer LM; Nguyen RT; Linden KG; Shiu J J Am Acad Dermatol; 2020 Feb; 82(2):440-459. PubMed ID: 31163235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]